HAWK Biosystems

HAWK Biosystems is a biotechnology startup based in Spain, founded in 2016 by Spanish and British scientists from the Francis Crick Institute in London. Formerly known as FASTBASE Solutions, the company aims to unveil protein function in patient samples to discover breakthrough biomarkers. Their flagship technology, QF-Pro®, allows for the discovery and quantification of novel biomarkers within any disease state with high precision. HAWK Biosystems addresses the increasing demand in biotechnology and healthcare industries by offering the QF-Pro® service, which is utilized to discover and quantify biomarkers in FFPE tissue and cell samples. Additionally, the company provides a custom assay creation service to cater to the specific needs of their clients. The company's innovative approach has attracted the attention of The European Innovation Council, which became their most recent investor with a grant investment at 28 February 2024. This investment signifies a recognition of the potential of HAWK Biosystems' technology to revolutionize the field of biomarker discovery and patient stratification for personalized treatment in various disease states.